1. Zent, C.S., et al., Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer, 2001. 92(5): p. 1325-30.
2. Baumann, T., et al., Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. Haematologica, 2014. 99(10): p. 1599-604.
3. Burger, J.A., et al., Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med, 2015. 373(25): p. 2425-37.
4. Woyach, J.A., et al., Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med, 2018. 379(26): p. 2517-2528.
5. Ahn, I.E., et al., Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood, 2017. 129(11): p. 1469-1479.
6. Burger, J.A., et al., Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun, 2016. 7: p. 11589.
7. Gángó, A., et al., Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. Int J Cancer, 2020. 146(1): p. 85-93.
8. Kiss, R., et al., Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia. Haematologica, 2019. 104(1): p. e38-e41.
9. Boissard, F., et al., Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients. Blood Cancer J, 2015. 5: p. e355.
10. Guo, A., et al., Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. Oncotarget, 2017. 8(8): p. 12953-12967.
11. Shen, Y., et al., Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment. Leuk Lymphoma, 2018. 59(8): p. 1927-1937.
12. Tissino, E., et al., Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med, 2018. 215(2): p. 681-697.
13. Damle, R.N., et al., B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood, 2002. 99(11): p. 4087-93.
14. Montraveta, A., et al., CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. Oncotarget, 2016. 7(5): p. 5507-20.
15. Ganghammer, S., et al., Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors. Haematologica, 2016. 101(3): p. e99-102.
16. Lafarge, S.T., et al., Differential expression and function of CD27 in chronic lymphocytic leukemia cells expressing ZAP-70. Leuk Res, 2015. 39(7): p. 773-8.
17. Sáez de Guinoa, J., et al., CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics. Blood, 2011. 118(6): p. 1560-9.
18. Takács, F., et al., The Effect of CD86 Expression on the Proliferation and the Survival of CLL Cells. Pathol Oncol Res, 2019. 25(2): p. 647-652.
19. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. World Health Organization Classification of Tumours, ed. F.T. Bosman, et al. 2017, Lyon: International Agency for Research on Cancer.
20. Hallek, M., et al., iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 2018. 131(25): p. 2745-2760.
21. Takács, F., et al., Identification of a novel resistance mechanism in venetoclax treatment and its prediction in chronic lymphocytic leukemia. Acta Oncol, 2021: p. 1-3.
22. Bodor, C., et al., Screening and monitoring of the BTK(C481S) mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. Br J Haematol, 2021. 194(2): p. 355-364.
23. Herishanu, Y., et al., The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood, 2011. 117(2): p. 563-74.
24. Long, M., et al., Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest, 2017. 127(8): p. 3052-3064.
25. Kondo, K., et al., Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia, 2018. 32(4): p. 960-970.
26. Niemann, C.U., et al., Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study. Clin Cancer Res, 2016. 22(7): p. 1572-82.
27. Rendeiro, A.F., et al., Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. Nat Commun, 2020. 11(1): p. 577.
28. Riether, C., C. Schürch, and A.F. Ochsenbein, Modulating CD27 signaling to treat cancer. Oncoimmunology, 2012. 1(9): p. 1604-1606.
29. Gobessi, S., et al., ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood, 2007. 109(5): p. 2032-9.
30. Del Poeta, G., et al., CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. Haematologica, 2012. 97(2): p. 279-87.
31. Herman, S.E., et al., Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood, 2014. 123(21): p. 3286-95.
32. Palma, M., et al., Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes. Br J Haematol, 2018. 183(2): p. 212-224.
33. Dai, Z.S., et al., Defective expression and modulation of B7-2/CD86 on B cells in B cell chronic lymphocytic leukemia. Int J Hematol, 2009. 89(5): p. 656-63.
34. Axelsson, S., et al., A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex. BMC Immunol, 2020. 21(1): p. 14.
35. Burger, J.A., et al., The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood, 2009. 114(16): p. 3367-75.
36. Lim, T.S., et al., CD80 and CD86 differentially regulate mechanical interactions of T-cells with antigen-presenting dendritic cells and B-cells. PLoS One, 2012. 7(9): p. e45185.
37. Huemer, M., et al., AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells. Eur J Immunol, 2014. 44(12): p. 3747-57.